



Scholars Research Library

Der Pharmacia Lettre, 2012, 4 (1):287-296

(<http://scholarsresearchlibrary.com/archive.html>)



Formulation and evaluation of rabeprazole sodium delayed release tablets

P. Suresh Kumar*, S. Navaneetha Krishnan, S. Pavani, Y. Surendarnath, S. Divya and Y. Sahithi

Browns College of Pharmacy, Khammam, Andhra Pradesh, India

ABSTRACT

The main purpose of this work is to develop delayed release stable tablet formulation of Rabeprazole sodium by direct compression and wet granulation method and enteric coating of tablets. All enteric coated tablets are delayed release tablets but all delayed release tablets are not enteric coated tablets. The present work aims to avoid degradation of drug in acidic environment of stomach. Preformulation studies like angle of repose, bulk density, tapped density, Carr's index, hausner's ratios, and drug/excipient compatibility study were conducted, five batches for direct compression and one batch for wet granulation were formulated and evaluated for hardness, friability, weight variation, drug content, disintegration and in-vitro dissolution. Among the six uncoated tablet batches F₅ and F₆ obtained good drug release profile compared to innovator. So batches F₅ and F₆ were selected for further steps of formulation i.e., sub coating and enteric coating. After enteric coated batches F₅ & F₆ were evaluated for acid resistance test and in-vitro dissolution test compared with innovator (ACIPHEX) found to be suitable for Rabeprazole sodium delayed release tablet. In case of stability studies, were conducted at 40°C/75% RH for 3 months. Impurities of these two batches F₅ & F₆, among these f₆ has shown increased amount of impurities than F₅. Based on the above data f₅ (Direct compression) batch was considered to be best formulation.

Key words: delayed release tablet, direct compression method, enteric coating tablet, wet granulation, Rabeprazole sodium.

INTRODUCTION

Rabeprazole sodium drug is a sodium salt of 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole belongs to a class of proton pump inhibitors (PPIs). It suppress gastric acid secretion by specifically inhibiting the H⁺/K⁺-ATPase enzyme system at the secretory surface of the gastric parietal cell [1]. Enteric coated tablets are solid unit dosage forms meant for oral administration and are designed to bypass the stomach [2] and release the

drug in small intestine. Rabeprazole sodium delayed release tablet are prepared by direct compression and wet granulation method and coated using polymers like OPadryOY-C-7240 clear and Instacoat EN-HPMCP yellow to delay the release. Rabeprazole used to treat duodenal and gastric ulcers and it is also used for the treatment of gastric oesophageal reflux disease [3]. Its half life is around 1-2 hrs. For once in day administration. The delayed release tablet is intended to release the drug after some delay or after tablet pass GI Tract. All enteric coated tablets are delayed release tablet but all delayed release tablet are not enteric coated tablets.

Delayed release dosage form is best formulations which are used for drugs that are destroyed in gastric fluids or cause gastric irritation, or are absorbed preferentially in the intestine. Such preparations contain an alkaline core material comprising the active substance, a separating layer & enteric coating layer [4]. The aim of proposed work was to formulate and characterize enteric coated tablets Rabeprazole sodium for delayed release of drug in stomach for treatment of gastric and duodenal ulcers.

MATERIALS AND METHODS

Rabeprazole sodium was obtained as gift sample from Hetro drugs. Crospovidone, silicodioxide, magnesium stearate, Mannitol, L-HPCLHII, Instacoat (EN-HPMCP) A34G00031, Opadry OY-C-7240 Clear were obtained as gift sample from apex pharmaceutical, Chennai.

Preparation of core Rabeprazole sodium tablets:

Direct compression method [5,6,7]

The enteric coating tablet was prepared by direct compression method. The weighed quantity of Rabeprazole sodium, mannitol, granular magnesium oxide and L-HPC LHII were sieved through 40 # size. The above shifted materials were lubricated with crospovidone, syloid and magnesium stearate for 5min octagonal blender. These blended materials were ready for compression. The different formulas were given in (Table 1).

Table 1: Formula for preparation of core tablets by direct compression method

| S. No | INGREDIENTS | Various Formulation Trials (mg/tab) | | | | |
|-------------------------------------|-------------------------------|-------------------------------------|------|------|------|------|
| | | F1 | F2 | F3 | F4 | F5 |
| 1. | Rabeprazole sodium | 20 | 20 | 20 | 20 | 20 |
| 2. | Mannitol | 83.5 | 68.5 | 68.0 | 47.5 | 37.0 |
| 3. | Granular magnesium oxide | 20 | 20 | 20 | 20 | 20 |
| 4. | L-HPCLHII | 10 | 10 | 10 | 10 | 10 |
| 5. | Crospovidone | 15 | 30 | 30 | 30 | 30 |
| 6. | Silicon dioxide(syloid Z44EP) | — | — | 0.5 | 1.0 | 1.5 |
| 7. | Magnesium stearate | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 |
| Total weight of the core tablet(mg) | | 150 | 150 | 150 | 150 | 150 |

Wet granulation Method:

All the ingredients including drugs and other excipients are mixed using cad mach miller except lubricant, then blender solution is added and passed through suitable sieve and granules are allowed to dry. Then lubricant is added to the dried granules and as sifted then compressed into a tablet using rotary punching machine (12 stations). The formula was given in (Table no: 2)

Table 2: Formula for preparation of core tablets by wet granulation method

| S.NO | INGREDIENTS | Trial Batch F (mg/tab) |
|-------------------------------------|--------------------------------|------------------------|
| 1. | Rabepazole sodium | 20 |
| 2. | Mannitol | 37 |
| 3. | Granular magnesium oxide | 50 |
| 4. | L-HPCLHII | 10 |
| 5. | Crospovidone | 30 |
| 6. | Silicon dioxide (syloid Z44EP) | 1.5 |
| 7. | Magnesium stearate | 1.5 |
| Total weight of the core tablet(mg) | | 150 |

From the above formulas F₅ for direct compression and F₆ for wet granulation batches have been selected for sub coating and enteric coating process due to its specification.

Procedure for preparation of sub coating of the core tablets:

Sub coating of the compressed tablets is achieved by standard coating pan technique. Coating solutions of opadryOY-C-7240 prepared separately with plasticizers in 5 % concentrations respectively. Thus solutions are applied over tablets using spray gun at appropriate pressure. The coated tablets are dried at 35-40°C for 10min .1%, 2%, 3%, and 4% of sub coating percentage has been given to the core tablet.

Procedure for preparation of enteric coating of the sub coated tablets:

The sub coated tablets are loaded into containing bed is warmed till the temperature reaches to 38⁰ C - 40⁰C. Then spray gun is switched on to spray the enteric coating dispersion using INSTACOAT EN-HPMCP Yellow in more than 12% of enteric coating percentage has been given to the sub coated tablets. The formula given in (Table no.3)

Table 3: Different combinations of sub coating & enteric coating percentages

| Trial batches | Sub coating (%) + Enteric coating (%) |
|------------------|---------------------------------------|
| F ₅ A | 1+22 |
| F ₅ B | 2+20 |
| F ₅ C | 3+18 |
| F ₅ D | 4+16 |
| F ₆ A | 2+12 |

Preformulation studies [8, 9, 10]

Angle of Repose

Angle of repose is the maximum angle that can be obtained between the free standing surfaces of the powder heap and the horizontal plane. It is a characteristic related to the interparticulate friction or resistance to movement between particles. The method used to find the angle of repose is to pour the powder in the form of a conical heap on a flat surface and measure the inclined angled with the horizontal pile.

$$\tan \theta = h/r$$

$$\theta = \tan^{-1}(h/r)$$

Where h = height of the heap
r = radius of the heap

Bulk density

Bulk density is given by the mass “m” of the powder occupying a known volume “v” according to the relationship

$$P_b = (m/v) \text{ g/cc}$$

It depends on particle size, shape, tendency of particle to adhere.

Tapped density

Weighed powder sample was transferred to a graduated cylinder and was placed on tapped density apparatus, was operated for a fixed number of taps (100). It is ratio of weight of sample to tapped volume.

$$\text{Tapped density} = \frac{\text{mass}}{\text{Tapped volume}}$$

Carr’s index

Based on the apparent bulk density and the tapped density, the percentage compressibility of the bulk drug was determined by using the following formula.

$$\% \text{ Compressibility} = \frac{\text{tapped density} - \text{bulkdensity}}{\text{tapped density}} * 100$$

Hausner’s ratio

The ratio of tapped density to bulk density of the powder is called the hausner ratio.

Drug/Excipient compatibility study

The objective of drug/excipient compatibility considerations and practical studies is to delineate, as quick as possible, real and possible interactions between potential formulation excipients and the active pharmaceutical excipient. Homogeneous mixtures of drug and excipients were prepared and filled in glass vials and self-seal LDPE (Low density Poly Ethylene) bags. The glass vials were maintained at $60 \pm 2^{\circ} \text{C}$ for 2 weeks. Those packed LDPE bags were maintained at $40 \pm 2^{\circ} \text{C} / 75 \pm 5\% \text{ RH}$ for 1 month. Controlled conditions ($2-8^{\circ} \text{C}$) maintained for comparison purpose.

Evaluation of core tablets:**Hardness test [11]**

Pfizer hardness tester was used for the determination of hardness of the tablets.

Thickness and diameter:

Thickness and diameter of the tablet were recorded during the process of compression using vernier calipers.

Friability:

10 tablets were accurately weighed and placed in the friabilator (VEEGO-tablet friabilator) and operated for 100 revolutions. The tablet were dedusted and reweighed. The tablets that loose less than 1% weight were considered to compliant.

Weight variation:

10 tablets were selected randomly from the 10% and weighed individually to check for weight variation.

Disintegration test [12]

Tablets were taken and introduced one tablet in each tube of disintegration apparatus and placed in 1 liter beaker and the time of disintegration was recorded. The study was done at room temperature.

Dissolution studies [13]

The *in-vitro* dissolution study was carried out in the USP dissolution (Electro lab) paddle type. 900ml of the dissolution medium was taken and the temperature was maintained at $37\pm 0.5^{\circ}\text{C}$. The speed of paddle was set at 100rpm. Sampling was done at regular intervals. For each sample 10ml of the dissolution medium was withdrawn and same amount was replaced. The sample was filtered and diluted with dissolution medium and then analyzed in UV-spectrophotometer. The absorbance was measured at 352 nm and % drug release was calculated.

In-vitro drug release for enteric coated tablets

Drug release studies were carried out using a USP type II dissolution test apparatus at 100rpm for 2hr in 0.1N HCL (900ml) maintained at $37\pm 0.5^{\circ}\text{C}$. 10ml of sample was taken and sample was analyzed using UV-spectrophotometer at 260nm. Then the dissolution medium was replaced with 0.6M tris buffer, pH 8.0 (900ml) and tested for drug release for 1 hr at same temperature and rotation speed. After 10, 20, 30, and 45mts, 10ml of the samples were taken out and 10ml volume of fresh tris buffer pH 8.0 was added to kept volume of dissolution medium constant and sample was analyzed using UV spectrophotometer at 284nm.

Accelerated stability studies of the optimized batch [14]

In order to determine the change in evaluation parameters and in-vitro release profile on storage, stability study of optimized batch F₅ D and F₆ A was carried out at accelerated storage condition at temperature $40^{\circ}\text{C}/75\%\text{RH}$ in a humidity chamber for 3 months. Sample were withdrawn after one week interval and evaluated for change in in-vitro drug release pattern, impurities.

RESULTS AND DISCUSSION

Preformulation studies:

From the results of micromeritic studies of the API, it was concluded that rabeprazole sodium has poor flow property and compressibility property. So, to improve the flow and compressibility property, it was beneficial to use the directly compressible grade components in the formulation tablets (Table no.4). Flow properties of powder, resistance to particle to particle movement can be judged by using angle of repose. This measurement gives qualitative and quantitative assessment of internal cohesive and frictional force under low level of externals. Load as might be applied in mixing and tablet compression. Values for angle of repose were found in the range of 26.1 - 44.9. The hausner's ratio of 0.45 - 0.64. The Carr's index ration was in the range of 7.46 - 25.0 & the tapped density ratio was in the range of 0.60 - 0.67. The prepared blends F₃, F₄, F₅ & F₆ showed good flow properties and since no interaction has occurred between the drug and all other excipients, the selected excipients were found to be compatible with drug (Table no.5)

Table 4: Micromeritic properties of API

| S. No | Characteristics | Results |
|-------|-----------------|---|
| 1 | Description | Off-white to pale yellow colored amorphous powder |
| 2 | Bulk density | 0.53gm/ml |
| 3 | Tapped density | 0.69gm/ml |
| 4 | Carr's index | 32.1% |
| 5 | Hausner's ratio | 4.17 |
| 6 | Angle of repose | 36 |

Table 5: Drug/ excipients Compatibility study

| S. No | Composition Details | D:E ratio | Observation at various storage conditions and durations | | | | | | |
|-------|---|-----------|---|-----------|----|----------|----|--------|----|
| | | | Initial | 40/75% RH | | 60± 2° C | | 2-8° C | |
| | | | | 2W | 4W | 1W | 2W | 2W | 3W |
| 1 | Rabepazole Sodium (D) | | Off White | NC | NC | NC | NC | NC | NC |
| 2 | D + Mannitol | 1:10 | Off White | NC | NC | NC | NC | NC | NC |
| 3 | D + MgO | 1:10 | Off White | NC | NC | NC | NC | NC | NC |
| 4 | D + L-HPC LH11 | 1:1 | Off White | NC | NC | NC | NC | NC | NC |
| 5 | D + Crospovidone | 1:1 | Off White | NC | NC | NC | NC | NC | NC |
| 6 | D + Syloid 244FP | 1:0.25 | Off White | NC | NC | NC | NC | NC | NC |
| 7 | D + Mg.Stearate | 1:0.25 | Off White | NC | NC | NC | NC | NC | NC |
| 8 | D + Opadry OY-C-7240 | 1:1 | Off White | NC | NC | NC | NC | NC | NC |
| 9 | D + Instacoat EN-HPMCP A34G00031 Yellow | 1:1 | Yellow | NC | NC | NC | NC | NC | NC |

Table 6: Physical parameters of Rabepazole sodium uncoated tablets

| Trial batch | Average wt(mg) | Thickness (m) | Hardness (kp) | Friability | Disintegration Time (min) |
|-------------|----------------|---------------|---------------|------------|---------------------------|
| F1 | 151.2 | 4.0 - 4.1 | 6 - 8 | 0.75 | 12 - 13 |
| F2 | 149.5 | 4.0 - 4.1 | 6 - 8 | 0.70 | 8 - 9 |
| F3 | 150.6 | 4.0 - 4.1 | 6 - 8 | 0.64 | 6 - 7 |
| F4 | 151.4 | 3.8 - 3.9 | 5 - 7 | 0.63 | 4 - 5 |
| F5 | 150.0 | 3.5- 3.6 | 5 - 7 | 0.69 | 2 - 3 |
| F6 | 150.2 | 3.5 - 3.6 | 9 - 11 | 0.56 | 5 - 6 |

Evaluation of core tablets:

The core tablet was evaluated for its thickness, friability, hardness, weight variation, and disintegration time. From the result it was found to be formulation F₁, F₂, F₃, F₄ were failed to comply with specification. Formulation F₅ (direct compression) and F₆ (Wet Granulation) batch shown that all parameters complies with the limit. The result shown in (Table no. 6)

By comparing the dissolution profile of all the individual and final batch core tablets with the innovator, the trial batch F₅ (direct compression method) and trial batch F₆ (wet granulation) has been found to show good drug releases (Table no.7) (fig.1)

Table 7: Dissolution test of core tablets

| Time interval | Innovator (AcipHex) | Trial batch formulations | | | | | |
|---------------|---------------------|--------------------------|----|----|----|----|----|
| | | F1 | F2 | F3 | F4 | F5 | F6 |
| 10 | 88 | 91 | 88 | 95 | 90 | 89 | 90 |
| 20 | 92 | 97 | 93 | 99 | 96 | 93 | 97 |
| 30 | 96 | 95 | 95 | 97 | 94 | 97 | 99 |
| 45 | 93 | 90 | 95 | 91 | 90 | 91 | 91 |

Fig 1: Dissolution profile for core tablet




Table 8: Acid resistance Test for 2 hours

| S. No | Trial Batches | % S,C+ %E.C | Result | Remarks |
|-------|------------------|-------------|--------|------------------------|
| 1 | F ₅ A | 1+8 | Failed | Tablet Opened |
| 2 | F ₅ B | 2+8 | Failed | Tablet opened |
| 3 | F ₅ C | 2+10 | Failed | Tablet opened |
| 4 | F ₅ D | 2+12 | Passed | Tablet remained intact |
| 5 | F ₆ A | 4+16 | Passed | Tablet remained intact |


Evaluation of enteric coated tablets:

Normally 2% is the minimum percentage for the sub coating and 12% is the minimum percentage for enteric coating that has to be applied to get a delayed release. In the evaluation of enteric coated tablets it was found that F₅A, F₅B, F₅C batches are failed because of low acid resistance in 0.1N Hcl, but batches F₅D (2% SC – 12% EC) and F₆A (4% SC – 16% EC) was found to have good acid resistance in 0.1N Hcl (Table No 8). *In-vitro* drug release for enteric coating tablets of selected batches F₅A, F₅B, F₅C, F₅D (Direct Compression) and F₆A (Wet Granulation) enteric coated tablets with that of the innovator (AcipHex). The dissolution profile of the trial batch F₅D (direct compression method) and F₆A (wet granulation method) have been found to show drug releases of 96% & 97 % (Table No 9) (Fig No:2).

Table 9: Dissolution test for Enteric coated tablets

| Time interval | Innovator (AcipHex) | F5A | F5B | F5C | F5D | F6A |
|---------------|---------------------|------|------|------|------|------|
| | | 1+22 | 2+20 | 3+18 | 4+16 | 2+12 |
| 10 | 21 | 0 | 0 | 10 | 19 | 22 |
| 20 | 86 | 0 | 20 | 70 | 89 | 94 |
| 30 | 90 | 20 | 75 | 96 | 94 | 96 |
| 45 | 94 | 54 | 96 | 91 | 97 | 98 |

Fig 2: Dissolution profile for Enteric Coating Tablet




After dissolution profiles of enteric coated tablets, the best formulation of trial batches such as F₅ D and F₆A compared with innovator in pH 8.0 buffer along with standard deviations were calculated (Table No.10)(Fig 3). So F₅ D and F₆A were considered to be carried out stability studies.

Table 10: Dissolution profiles of best formulation with innovator along with standard deviation in pH 8.0 tris buffer

| Time intervals | AcipHex DR%± SD | F ₅ D DR%± SD | F ₆ A DR%± SD |
|----------------|-----------------|--------------------------|--------------------------|
| 10 | 21±0.56 | 19±0.96 | 22±1.5 |
| 20 | 86±0.95 | 89±1.25 | 94±0.6 |
| 30 | 90±0.70 | 94±0.75 | 96±0.7 |
| 45 | 94±1.0 | 97±0.45 | 98±1.0 |

Fig. 3: Dissolution profiles of best formulation with innovator along with standard deviation in pH 8.0 tris buffer



Finally Rabeprazole sodium DR tablets batch F₅D & F₆A kept for its stability at different storage condition at 40° C/75%RH for 3 months of stability studies, a very minute difference have been found between those values. For F₆A batch has shown increased amount of impurities than F₅D batch indicating a stability problem in F₆A batch (Table No 11). Based on the above stability

data F₅D batch prepared by direct compression method has been selected as the optimized formulation (Table No 12)

Table 11: Stability test data of F₅D & F₆A Batches

| Test | F ₅ D Direct compression | | | | F ₆ D Wet granulation | | | |
|---------------------------|--|-------|-------|-------|-------------------------------------|-------|-------|------|
| | Initial | 1m | 2m | 3m | Initial | 1m | 2m | 3m |
| Acid resistance (%) | 100.9 | 100.1 | 99.9 | 99.2 | 100.6 | 100.0 | 99.7 | 98.9 |
| Impurities (%) | 0.562 | 0.634 | 0.656 | 0.745 | 0.596 | 0.692 | 0.796 | 1.06 |
| % Cumulative drug release | 100 | 99.8 | 99.0 | 98.5 | 99 | 98.6 | 98.0 | 97.2 |

Table 12: Formula for preparation of Enteric coated tablets by Direct compression method

| S.NO | INGREDIENTS | Trial Batch F (mg/tab) |
|-------------------------------------|---|------------------------|
| 1. | Rabeprazole sodium | 20 |
| 2. | Mannitol | 37 |
| 3. | Granular magnesium oxide | 50 |
| 4. | L-HPCLHII | 10 |
| 5. | Crospovidone | 30 |
| 6. | Silicon dioxide (syloid Z44EP) | 1.5 |
| 7. | Magnesium stearate | 1.5 |
| Total weight of the core tablet(mg) | | 150 |
| 8 | Sub Coating (Opadry OY-C-7240 Clear) | 4% |
| 9 | Enteric Coating(Instacoat EN-HPMCP) A34G00031 Yellow | 16% |
| Final weight of the tablet | | 170mg |

CONCLUSION

Attempts were made in the present investigation to prepare a stable composition of delayed release tablets of rabeprazole sodium. These results clearly reflect that the prepared formulation offers effective resistance in acidic environment and starts its release in the alkaline environment of small intestine. Thus, Instacoat EN-HPMCP A34G00031 Yellow can be successfully employed to retard the release pattern of rabeprazole sodium thereby enhancing the therapeutic efficacy. The final formulation also shows good comparative dissolution profile with marketed preparation.

Acknowledgement

Browns college of pharmacy management for granting permission for the publication of this work.

REFERENCES

- [1]. Sanjiv Arora; Deepak K.Aneja; Mahesh Kumar and Om Prakash. *Der Pharmacia Lettre*. **2011**,3(3), 272-279
- [2]. HA. Libermen; L.Lachman "Pharmaceutical Dosage Forms" Tablets.2nd edition. Marcel Dekker Inc, New York, 3,. **2005**, 85-143
- [3]. GC. Cole. "Pharmaceutical Coating Technology" 3rd edition, Taylor and Francis Ltd; New York **1998**. 6- 52.
- [4]. L. Lachman; HA Liberman; JL Kanig. "The Theory and Practice of Industrial Pharmacy" 3rd edition, Varghese Publishing house, Bombay.**2005** 371-372

- [5]. R. Jain; C. Jindal; S. Singh. Pharmaceutical composition comprising of proton pump inhibitor and prokinetic agent. U.S. patent No 2007/0160664A1; 2007.
- [6]. R. Dietrich Ney. Oral administration form for pyridine-2-methyl sulfinyl-1H-benzimidazoles. U.S patent No. US 7041313 B1; 2006.
- [7]. S. Aoki. Preparation composition containing acid unstable physiologically active compound and process for producing same. U.S patent No. US 2005/0163846 A1; 2005.
- [8]. J. Cooper; C. Gun "Tutorial Pharmacy" 12th edition CBS publication and distributors, New Delhi, 1986. 211-233
- [9]. M.E. Aulton, "Pharmaceutics" The Science of Dosage form design 2nd edition, Churchill Livingstone, England **2002**, 247.
- [10]. A. Martin "physical pharmacy and pharmaceutical sciences". 5th edition, New York Lippincott Williams and Wilkins; **2001**, 423-454
- [11]. S.A. Sreenivas; A.P Gadad . *Indian drugs*, **2006**, 43(1), 35-38.
- [12]. R. Ziyaur; RK. Mushira, khar. *acta pharm*, **2006**, 56, 49-57.
- [13]. Indian Pharmacopoea. The Controller of Publications, Ministry of Health and Family Welfare, Government of India, New Delhi, **1996**, A-80, 2
- [14] ICH, Accelerated stability testing of new drug substances and products, Geneva. International conference on Harmonization Nov **1996**.